Skip to main content
Premium Trial:

Request an Annual Quote

David Hastings New Incyte CFO; Darlene Solomon Promoted to Agilent Labs VP; Mary Holland, Mark Meyers Join EraGen as VPs of Sales and Marketing; and Others

NEW YORK (GenomeWeb News) Oct. 1 - David Hastings has been appointed executive vice president and chief financial officer of Incyte, to replace the current CFO, John Vuko, the Palo Alto, Calif., and Wilmington, Del., company said today.


Hastings comes to Incyte from ArQule, where he has served as CFO and treasurer since 2000. Before joining ArQule, Hastings was vice president and corporate controller of Genzyme, and prior to that, was director of finance at Sepracor. From 1985 to 1994, Hastings was an accountant with PriceWaterhouseCoopers, and was involved in initial and follow-on offerings for biotechnology companies.


Vuko, who has been Incyte's CFO since December 1999, will remain as an advisor to Incyte "for a period of time," the company said.

Steve Trevisan, executive vice president and a director of Gene Logic, will step down, but will continue "in an advisory capacity" until the end of the year, the company said today.


Trevisan joined Gene Logic in April as part of its acquisition of Therimmune Research, of which he was president and CEO. The resignation of Trevisan, which the company said was by "mutual agreement of the parties," comes as Gene Logic moves to integrate fully Therimmune Research under the Gene Logic brand name.


Trevisan founded TherImmune in December 1998. Prior to this, he was president of Perot Systems Communications, which does billing systems for the telecommunications industry, and before that, was president and CEO of CommSys, an outsource billing provide. Trevisan also founded National Clinical Resarch Centers and was head of strategic business development at Pansophic systems.


Karen Dawes has been named to the board of directors of Genaissance Pharmaceuticals, the New Haven, Conn., company said today.


Dawes is principal at the consulting group Knowledgeable Decisions, LLC, which focuses on biotech and emerging pharma companies. She has previously worked as senior vice president and US Business group head at Bayer, and also has worked at Wyeth Pharmaceuticals, Genetics Institute, and Pfizer. Dawes is also on the board of directors at Protein Design Labs.



Darlene Solomon has been named vice president and director of Agilent Laboratories, to replace Tom Saponas, who is retiring, the company said Sept. 30.

Solomon serves on the National Science Foundation's External Advisory Board for its Nanobiotechnology Center and the policy board for the Defense Advanced Research Projects Agency Center for Biochemical Optoelectronic Microsystems.


At Agilent, Solomon was most recently director of Agilent Labs' life science technologies laboratory, and was a senior director of research and development/technology for the company's life sciences and chemical analysis business.  She joined Hewlett-Packard Laboratories-which later spun off Agilent-in 1984, as a technical staffer. Prior to joining industry, Solomon was a researcher at Stanford University and MIT.


Mary Holland and Mark Meyers have been appointed vice presidents of sales and marketing at EraGen Biosciences, the Madison, Wis., company said Sept. 29.


Holland, who will focus on marketing and sales of EraGen's Aegis synthetic DNA product, comes to the company from Nanogen, where she was senior director of worldwide corporate accounts.


Meyers, who will develop sales and marketing strategies for the company's Master Catalog proteomics system, was previously vice president of sales for Scimagix.


Gail Mederis has been appointed president and CEO of Five Prime Therapeutics, of San Francisco, replacing company founder Lewis Williams, the company said Sept. 23.


Williams will continue in a role as executive chairman and leader of the company's research.


Maderis comes to Five Prime from Genzyme, where she was corporate vice president and president of Genzyme Molecular Oncology.  Prior to joining Genzyme, Maderis held posts at Bain & Company and Shell Oil.


Five Prime uses the "pharmanome," the set of pharmaceutically relevant proteins, to screen for therapeutic leads.

William Linton has joined the board of directors of High Throughput Genomics, the Tuscon, Ariz., company said Sept. 23.


Linton is a founder and CEO of Promega, as well as a director for Bruker Biosciences and a member of the advisory board for the Medical College of Wisconsin's cardiovascular center, as well as the Wisconsin Technology Council.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.